局部药物 CDMO 市场 - 按产品类型、治疗领域、服务类型、最终用户、全球预测

Topical Drugs CDMO Market - By Product Type, Therapeutic Area, Service Type, End-user, Global Forecast

出版日期: 2024年04月22日 | 出版商:

Global Market Insights Inc. | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在消费者对非处方产品偏好增强的推动下，2024 年至 2032 年全球外用药物 CDMO 市场复合年增长率将超过 12.1%。随着消费者寻求方便且具成本效益的医疗保健解决方案，对霜剂和药膏等非处方药局部治疗的需求正在上升。这些产品在零售和网路药局的供应量不断增加，也支持了这一趋势。

随着製药公司外包非处方药产品的开发和製造以满足需求，CDMO 受益于此转变。因此，对自我保健和轻鬆获得非处方药的关注继续推动外用药物的 CDMO 市场。最近的一项杂货店Doppio 调查显示，70% 的消费者尝试过自有品牌产品，其中50% 的消费者计划在2024 年继续购买这些产品。有品牌。

外用药物 CDMO 产业根据产品类型、治疗领域、服务类型、最终用户和地区进行分类。

外用药物CDMO 市场的液体製剂部分将在2024 年至2032 年间经历显着的复合年增长率。应用的首选。此细分市场的成长得益于配方技术的创新和消费者对液体保养品的偏好增加。製药公司越来越多地将液体外用药物的开发和製造外包给 CDMO，以利用他们的配方开发和监管合规专业知识，推动这一专业领域的市场扩张。

由于全球慢性疼痛的盛行率不断增加，到 2032 年，疼痛管理领域将获得相当大的外用药物 CDMO 市场份额。外用製剂可提供非侵入性和局部疼痛缓解，是寻求口服药物替代品的患者的首选。这一趋势得到了透皮给药技术进步的支持，并提高了局部疼痛治疗的功效和安全性。製药公司正在利用 CDMO 在製剂开发和製造方面的专业能力，以满足对创新局部疼痛管理解决方案不断增长的需求，并推动这一专业细分市场的扩张。

亚太地区外用药物 CDMO 市场规模在预测期间内将呈现显着的复合年增长率。医疗保健支出的增加、慢性皮肤病患病率的增加以及药品市场的扩张正在推动成长。亚太地区人口众多、医疗基础设施改善以及监管改革为 CDMO 创造了机会。公司越来越多地外包外用药物的开发和製造，以利用该地区熟练的劳动力和具有成本效益的製造能力。随着亚太地区继续成为医药创新和生产中心，外用药物专业 CDMO 服务的需求预计将大幅成长。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Ascendia Pharmaceuticals
Bora Pharmaceutical CDMO
Cambrex Corporation
Contract Pharmaceuticals Limited
DPT Laboratories, Ltd.
The Lubrizol Corporation
MedPharm Ltd
PCI Pharma Services
Pierre Fabre Group
Piramal Pharma Solutions

」

简介目录

Product Code: 9137

Global Topical Drugs CDMO Market will witness over 12.1% CAGR from 2024 to 2032, spurred by the strengthening consumer preference for over-the-counter products. As consumers seek convenient and cost-effective healthcare solutions, the demand for OTC topical treatments, such as creams and ointments, is rising. This trend is supported by the increasing availability of these products in retail and online pharmacies.

CDMOs benefit from this shift as pharmaceutical companies outsource the development and manufacturing of OTC products to meet demand. Consequently, the focus on self-care and easy access to OTC medications continue to bolster the CDMO market for topical drugs. A recent grocery doppio survey reveals that 70% of consumers have tried private-label products, with 50% planning to continue purchasing them into 2024. This trend indicates a growing shift towards private labels in the retail market.

The topical drugs CDMO industry is classified based on product type, therapeutic area, service type, end-user, and region.

The liquid formulation segment in the topical drugs CDMO market will experience a notable CAGR between 2024 and 2032. Liquid formulations offer advantages such as ease of application, faster absorption, and potential for precise dosing, making them preferred for various dermatological and cosmetic applications. This segment's growth is ushered by innovations in formulation techniques and increased consumer preference for liquid-based skincare products. Pharmaceutical companies are increasingly outsourcing liquid topical drug development and manufacturing to CDMOs to capitalize on their formulation development and regulatory compliance expertise, fueling market expansion in this specialized area.

The pain management segment will garner considerable topical drugs CDMO market share by 2032 because of the increasing prevalence of chronic pain conditions globally. Topical formulations offer non-invasive and localized pain relief, preferred by patients seeking alternatives to oral medications. This trend is supported by advancements in transdermal delivery technologies, enhancing the efficacy and safety profiles of topical pain treatments. Pharmaceutical companies are leveraging CDMOs' specialized capabilities in formulation development and manufacturing to meet the rising demand for innovative topical pain management solutions, driving expansion in this specialized market segment.

Asia Pacific topical drugs CDMO market size will exhibit a significant CAGR during the forecast period. Rising healthcare expenditure, increasing prevalence of chronic skin conditions, and expanding pharmaceutical markets are driving growth. Asia Pacific's large population and improved healthcare infrastructure and regulatory reforms foster opportunities for CDMOs. Companies are increasingly outsourcing topical drug development and manufacturing to capitalize on the region's skilled workforce and cost-effective manufacturing capabilities. As Asia Pacific continues to emerge as a hub for pharmaceutical innovation and production, the demand for specialized CDMO services in topical drugs is expected to rise significantly.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing demand for topical medications
  - 3.2.1.2 Growing adoption of outsourcing of manufacturing activities
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Challenges in quality control
  - 3.2.2.2 High capital investment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Semi-solid formulations
- 5.2.1 Creams
- 5.2.2 Ointments
- 5.2.3 Gels
- 5.2.4 Other semi-solid formulations
5.3 Liquid formulation
5.4 Trans dermal products
5.5 Solid formulations

Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Dermatology
6.3 Pain management
6.4 Wound care
6.5 Ophthalmology
6.6 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By Service Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Contract manufacturing
7.3 Contract development

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Pharmaceutical companies
8.3 Biotechnology companies
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa